AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	128.51	156.33	133.32	386.54	476.14
Short-Term Investments	405.31	469.29	627.27	499.95	246.84
Cash & Short-Term Investments	533.83	625.61	760.59	886.49	722.98
Cash Growth	-14.67%	-17.75%	-14.20%	22.62%	21.69%
Accounts Receivable	58.29	33.62	30.59	38.59	160.58
Other Receivables	55.7	26.53	33.79	64.82	14.28
Receivables	153.4	92.13	64.38	103.41	174.86
Inventory	6.34	-	-	1.53	1.67
Prepaid Expenses	9.67	8.63	22.02	9.06	5.29
Restricted Cash	25	25	25	25	25
Total Current Assets	728.23	751.37	871.99	1,025	929.8
Property, Plant & Equipment	428	340.43	287.7	217.26	111.62
Long-Term Investments	94.88	114.8	65.94	34.42	32.31
Goodwill	47.81	47.81	47.81	47.81	47.81
Other Intangible Assets	38.38	42.11	120.43	131.5	148.39
Other Long-Term Assets	19.65	34.44	80.34	40.83	30.64
Total Assets	1,357	1,361	1,488	1,541	1,319
Accounts Payable	25.23	34.35	28.6	14.83	14.92
Accrued Expenses	10.76	8.38	7.71	25.8	26.54
Current Portion of Leases	5.82	4.62	6.16	5.58	3.65
Current Income Taxes Payable	-	-	-	-	35.68
Current Unearned Revenue	22.51	21.18	26.07	27.9	12.01
Other Current Liabilities	-	8.09	50.48	44.21	27.87
Total Current Liabilities	64.31	76.61	119.01	118.32	120.68
Long-Term Leases	137.4	60.74	71.22	76.68	36.41
Long-Term Unearned Revenue	174.45	149.89	104.11	60.32	60.76
Long-Term Deferred Tax Liabilities	9.12	10.05	30.61	33.18	37.37
Other Long-Term Liabilities	4.77	7.17	10.82	19.14	37.62
Total Liabilities	390.05	304.47	335.78	307.63	292.84
Common Stock	802.34	777.17	753.2	734.37	722.43
Additional Paid-In Capital	198.28	166.36	121.05	74.12	35.36
Retained Earnings	-29.48	116.93	279.79	426.19	267.67
Comprehensive Income & Other	-4.23	-4.38	-1.72	-1.39	0.28
Total Common Equity	966.9	1,056	1,152	1,233	1,026
Shareholders' Equity	966.9	1,056	1,152	1,233	1,026
Total Liabilities & Equity	1,357	1,361	1,488	1,541	1,319
Total Debt	143.22	65.36	77.38	82.26	40.07
Net Cash (Debt)	390.61	560.25	683.21	804.23	682.91
Net Cash Growth	-30.28%	-18.00%	-15.05%	17.76%	15.80%
Net Cash Per Share	1.31	1.90	2.36	2.55	2.15
Filing Date Shares Outstanding	303.16	297.99	292.78	287.69	283.92
Total Common Shares Outstanding	300.6	295.76	290.82	286.85	283.26
Working Capital	663.93	674.76	752.97	907.17	809.12
Book Value Per Share	3.22	3.57	3.96	4.30	3.62
Tangible Book Value	880.72	966.17	984.09	1,054	829.54
Tangible Book Value Per Share	2.93	3.27	3.38	3.67	2.93
Land	53.41	53.41	53.41	53.41	33.04
Buildings	193.16	175.81	43.95	11.36	1.21
Machinery	102.94	84.29	73.87	49.56	26.65
Leasehold Improvements	-	-	73.94	40.57	22.75

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q